Search Results - "Balañá, C"

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary by Losa, F., Iglesias, L., Pané, M., Sanz, J., Nieto, B., Fusté, V., de la Cruz-Merino, L., Concha, Á., Balañá, C., Matías-Guiu, X.

“…Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original…”
Get full text

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study by González-Martín, A. J., Calvo, E., Bover, I., Rubio, M. J., Arcusa, A., Casado, A., Ojeda, B., Balañá, C., Martínez, E., Herrero, A., Pardo, B., Adrover, E., Rifá, J., Godes, M. J., Moyano, A., Cervantes, A.

“…Background:: The aim of this study was to determine whether the response rate for the paclitaxel–carboplatin combination is superior to carboplatin alone in…”
Get full text

SEOM clinical guidelines for anaplastic gliomas (2017) by Balañá, C., Alonso, M., Hernandez, A., Perez-Segura, P., Pineda, E., Ramos, A., Sanchez, A. R., Teixidor, P., Verger, E., Benavides, M.

“…The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic…”
Get full text

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma by Sepúlveda, J. M., Belda-Iniesta, C., Gil-Gil, M., Pérez-Segura, P., Berrocal, A., Reynés, G., Gallego, O., Capellades, J., Ordoñez, J. M., La Orden, B., Balañá, C.

“…Purpose The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in…”
Get full text

2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation by Sepúlveda, J.M, Vaz, M.A, Gil, M, Reynés, G, Gallego, O, Bolós, M.V, Laýn, A. Hernádez, Sánchez-Gómez, P, Martýnez, M, Vicente, E, Quindos, M, Luque, R, Ramos, A, Ruano, Y, Manneh, R, Segura, P. Pérez, Benavides, M, Balañá, C

Get full text

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) by Balañá, C., Alonso, M., Hernandez-Lain, A., Perez-Segura, P., Pineda, E., Ramos, A., Sanchez, A. R., Teixidor, P., Verger, E., Benavides, M.

“…The SEOM/GEINO clinical guidelines provide recommendations for radiological, and molecular diagnosis, treatment and follow-up of adult patients with anaplastic…”
Get full text

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain by Balañá, C., Vaz, M. A., Lopez, D., de la Peñas, R., García-Bueno, J. M., Molina-Garrido, M. J., Sepúlveda, J. M., Cano, J. M., Bugés, C., Sanz, S. M., Arranz, J. L., Perez-Segura, P., Rodriguez, A., Martin, J. M., Benavides, M., Gil, M.

“…Purpose The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide…”
Get full text

Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns by Comas, S., Luguera, E., Molero, J., Balaña, C., Estival, A., Castañer, S., Carrato, C., Hostalot, C., Teixidor, P., Villà, S.

“…Background There is growing evidence that the subventricular zone (SVZ) may be involved in both the initiation and progression of glioblastoma (GB). We aimed…”
Get full text

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry by Gallego, Oscar, Cuatrecasas, M., Benavides, M., Segura, P. P., Berrocal, A., Erill, N., Colomer, A., Quintana, M. J., Balaña, C., Gil, M., Gallardo, A., Murata, P., Barnadas, A.

“…Epidermal growth factor receptor gene ( EGFR ) alteration is a common feature in most of glioblastoma multiforme (GBM). Robust response of anti-EGFR treatments…”
Get full text

Patterns of relapse in glioblastoma after neoadjuvancy and radiation therapy by Comas, S, Villà, S, Etxaniz, O, Domènech, S, Hostalot, C, Carrato, C, Bugès, C, Balañá, C

Get full text

Phase I II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study by LOPEZ-POUSA, A, LOSA, R, MARTINEZ-TRUFERO, J, ESTEBAN, E, BUESA, J. M, MARTIN, J, MAUREL, J, FRA, J, SIERRA, M, CASADO, A, GARCIA DEL MURO, J, POVEDA, A, BALANA, C

“…The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult…”
Get full text

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma by Gately, L., Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Hong, W., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

“…Purpose The optimal duration of post-radiation temozolomide in newly diagnosed glioblastoma remains unclear, with no published phase III randomised trials…”
Get full text

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM) by Gately, Lucy, Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

“…Purpose The impact of age on optimal management of glioblastoma remains unclear. A recent combined analysis of two randomised trials, GEINO14-01 and EX-TEM,…”
Get full text

Extended-schedule dose-dense temozolomide in refractory gliomas by Berrocal, A., Perez Segura, P., Gil, M., Balaña, C., Garcia Lopez, J., Yaya, R., Rodríguez, J., Reynes, G., Gallego, O., Iglesias, L.

“…This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in…”
Get full text

Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas A study of the Spanish Group for Research in Sarcomas (GEIS) by Poveda, A., López-Pousa, A., Martín, J., Del Muro, J. García, Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M. D., Escudero, P., Cruz, J., Belyakova, Elena, Menéndez, D., Buesa, J. M.

“…Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients…”
Get full text

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma by Gately, L., Mesía, C., Sepúlveda, J. M., del Barco, S., Pineda, E., Gironés, R., Fuster, J., Hong, W., Dumas, M., Gill, S., Navarro, L. M., Herrero, A., Dowling, A., de las Peñas, R., Vaz, M. A., Alonso, M., Lwin, Z., Harrup, R., Peralta, S., Long, A., Perez-Segura, P., Ahern, E., Garate, C. O., Wong, M., Campbell, R., Cuff, K., Jennens, R., Gallego, O., Underhill, C., Martinez-Garcia, M., Covela, M., Cooper, A., Brown, S., Rosenthal, M., Torres, J., Collins, I. M., Gibbs, P., Balana, C.

Get full text

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial by Gao, Y., Weenink, B., van den Bent, M.J., Erdem-Eraslan, L., Kros, J.M., Sillevis Smitt, PAE, Hoang-Xuan, K., Brandes, A.A., Vos, M., Dhermain, F., Enting, R., Ryan, G.F., Chinot, O., Ben Hassel, M., van Linde, M.E., Mason, W.P., Gijtenbeek, J.M.M., Balana, C., von Deimling, A., Gorlia, Th, Stupp, R., Hegi, M.E., Baumert, B.G., French, P.J.

“…The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ)…”
Get full text

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma by Cardona, A. F., Rojas, L., Wills, B., Ruiz-Patiño, A., Abril, L., Hakim, F., Jiménez, E., Useche, N., Bermúdez, S., Mejía, J. A., Ramón, J. F., Carranza, H., Vargas, C., Otero, J., Archila, P., Rodríguez, J., Behaine, J., González, D., Jacobo, J., Cifuentes, H., Feo, O., Penagos, P., Pineda, D., Ricaurte, L., Pino, L. E., Vargas, C., Marquez, J. C., Mantilla, M. I., Ortiz, L. D., Balaña, C., Rosell, R., Zatarain-Barrón, Z. L., Arrieta, O.

“…Purpose Patients with recurrent glioblastoma (rGBM) have a poor prognosis, with survival ranging from 25 to 40 weeks. Antiangiogenic agents are widely used,…”
Get full text

Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between ocreotide in combination with everolimus compared to sunitinib by Cardona Zorrilla, A.F., Ruiz-Patiño, A., Arrieta, O., Zatarain-Barron, L., Hakim, F., Jimenez, E., Mejia, J.A., Ramon, F., Useche, N., Bermudez, S., Pineda, D., Cifuentes, H., Rojas, L.L., Pino Villareal, L.E., Balana, C.

Get full text

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients by Balaña, C., Estival, A., Teruel, I., Hardy-Werbin, M., Sepulveda, J., Pineda, E., Martinez-García, M., Gallego, O., Luque, R., Gil-Gil, M., Mesia, C., Del Barco, S., Herrero, A., Berrocal, A., Perez-Segura, P., De las Penas, R., Marruecos, J., Fuentes, R., Reynes, G., Velarde, J. M., Cardona, A., Verger, E., Panciroli, C., Villà, S.

“…Purpose We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected…”
Get full text